Published in AIDS Weekly, December 11th, 1995
The FDA authorized the use of 3TC in combination with AZT, after only 4-1/2 months of review. The drug's manufacturer must now demonstrate that the therapy produces "clinical benefits," such as a reduction of opportunistic infections, the FDA said.
Glaxo Wellcome Inc., Research Triangle Park, North Carolina, makes both 3TC and AZT. It found that when the two drugs are paired, 3TC appears to boost immune systems and lower the amount of HIV in the blood...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.